Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs

BACKGROUND: Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L‐asparaginase (L‐ASP) has not been studied. HYPOTHESIS/OBJECTIVES: To evaluate the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Cawley, Jacob R., Wright, Zachary M., Meleo, Karri, Post, Gerald S., Clifford, Craig A., Vickery, Kathryn R., Vail, David M., Bergman, Philip J., Thamm, Douglas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096650/
https://www.ncbi.nlm.nih.gov/pubmed/32064697
http://dx.doi.org/10.1111/jvim.15723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096650/
https://www.ncbi.nlm.nih.gov/pubmed/32064697
http://dx.doi.org/10.1111/jvim.15723

Ejemplares similares